

ESMO PRECEPTORSHIP PROGRAMME COLORECTAL CANCER

Multidisciplinary management, standards of care
and future perspectives

Valencia, Spain
13-14 May 2022

CO-CHAIRS: Andrés Cervantes, Spain
Pia Österlund, Finland

SPEAKERS: Dirk Arnold, Germany
Regina Beets-Tan, Netherlands
Dimitri Dorcaratto, Spain
Michel Ducreux, France
Eduardo García-Granero, Spain
Robert Glynne-Jones, United Kingdom
Erika Martinelli, Italy
Iris Nagtegaal, Netherlands
Jenny Seligmann, United Kingdom
Elizabeth Smyth, United Kingdom
Karen-Lise Garm Spindler, Denmark

LEARNING OBJECTIVES

- To learn about best clinical practice in the multidisciplinary management of colorectal cancer in the adjuvant and metastatic settings
- To understand the importance of pathology, histo- and moleculopathological prognostic factors
- To learn about sequencing of treatments, adverse events and special situations

ACCREDITATION

The programme of this event has been accredited with **10 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4, 6900 Lugano, Switzerland
Email: courses@esmo.org
www.esmo.org



Friday, 13 May 2022

09:00-09:15 15'	Welcome and introduction	Chairs: Andrés Cervantes, ES Pia Österlund, FI
09:15-10:35 80'	SESSION 1 Localised colorectal cancer	Chairs: Andrés Cervantes, ES Pia Österlund, FI
20'	Optimal loco-regional staging for colorectal cancer	Regina Beets-Tan, NL
20'	Standards of surgical practice for resectable colon and rectal cancer	Eduardo García-Granero, ES
30'	Quality and rules of a good pathology report Histo- and moleculopathological biomarkers	Iris Nagtegaal, NL
10'	Q&A	Faculty
10:35-11:00	Coffee break	
11:00-11:40 40'	SESSION 2 Controversy: Is total neoadjuvant treatment a new standard of care in locally advanced rectal cancer?	Chair: Pia Österlund, FI
15'	Ready for prime time	Andrés Cervantes, ES
15'	Not yet	Robert Glynne-Jones, UK
10'	Q&A	Faculty
11:40-13:00 80'	SESSION 3 Adjuvant and neoadjuvant treatment in colon cancer	Chair: Pia Österlund, FI
30'	Adjuvant treatment for colon cancer stage II and III as standard of care	Michel Ducreux, FR
20'	Neoadjuvant treatment for localised colon cancer as a potential option	Jenny Seligmann, UK
30'	Participants clinical case discussion (x4)	Faculty
13:00-14:00	Lunch	
14:00-15:25 85'	SESSION 4 Current first-line treatment for metastatic colorectal cancer	Chair: Andrés Cervantes, ES
40'	Current treatment of metastatic colorectal cancer: Basic strategies according to subgroups	Erika Martinelli, IT
45'	Presentation of three challenging clinical cases and faculty discussion	Jenny Seligmann, UK
15:25-16:00	Coffee break	
16:00-17:45 105'	SESSION 5 Metastatic colorectal cancer: Special clinical situations	Chair: Pia Österlund, FI
30'	Oligometastatic colorectal cancer: What to know about it and how to treat it	Pia Österlund, FI
30'	How to integrate surgery in the treatment of patients with liver-only metastatic disease	Dimitri Dorcaratto, ES
15'	How to deal with patients having isolated peritoneal metastases	Michel Ducreux, FR
30'	Participants clinical case discussion (x3)	Faculty
20:30	Dinner	

Saturday, 14 May 2022

08:30-10:10 100'	SESSION 6 Metastatic colorectal cancer: Maintenance and further lines	Chair: Andrés Cervantes, ES
30'	The role of maintenance therapy and treatment pauses	Dirk Arnold, DE
30'	What to do after first-line failure?	Pia Österlund, FI
30'	Management of treatment-related side effects: <ul style="list-style-type: none"> - GI-toxicity - Neuropathy - Skin toxicity - Hypertension - Hand-foot syndrome 	Michel Ducreux, FR
10'	Q&A	Faculty
10:10-10:40	Coffee break	
10:40-11:20 40'	SPECIAL LECTURE Immunotherapy in colorectal cancer	Chair: Pia Österlund, FI
30'	Immunotherapy in colorectal cancer	Elizabeth Smyth, UK
10'	Q&A	Faculty
11:20-12:00 40'	SESSION 7 Anal canal tumours	Chair: Andrés Cervantes, ES
30'	Standard of care for anal canal squamous carcinomas	Karen-Lise Garm Spindler, DK
10'	Q&A	Faculty
12:00-12:30 30'	SESSION 8 Metastatic colorectal cancer: Case discussion	Chairs: Andrés Cervantes, ES Pia Österlund, FI
30'	Participants clinical case discussion (x3)	Faculty
12:30-12:45 15'	Conclusion and farewell	Andrés Cervantes, ES Pia Österlund, FI
12:45-13:45	Lunch	

Note: Each 10-minute slot for clinical case discussion includes 5' case presentation and 5' Q&A / panel discussion